PMID- 24363026
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20171116
IS  - 1432-0738 (Electronic)
IS  - 0340-5761 (Linking)
VI  - 88
IP  - 3
DP  - 2014 Mar
TI  - Comparison of intake and systemic relative effect potencies of dioxin-like 
      compounds in female rats after a single oral dose.
PG  - 637-46
LID - 10.1007/s00204-013-1186-2 [doi]
AB  - Risk assessment for mixtures of dioxin-like compounds uses the toxic equivalency 
      factor (TEF) approach. Although current WHO-TEFs are mostly based on oral 
      administration, they are commonly used to determine toxicity equivalencies (TEQs) 
      in human blood or tissues. However, the use of "intake" TEFs to calculate 
      systemic TEQs in for example human blood, has never been validated. In this 
      study, intake and systemic relative effect potencies (REPs) for 
      1,2,3,7,8-pentachlorodibenzo-p-dioxin (PeCDD), 2,3,4,7,8-pentachlorodibenzofuran 
      (4-PeCDF), 3,3',4,4',5-pentachlorobiphenyl (PCB-126), 
      2,3',4,4',5-pentachlorobiphenyl (PCB-118) and 2,3,3',4,4',5-hexachlorobiphenyl 
      (PCB-156) were compared in rats. The effect potencies were calculated based on 
      administered dose and liver, adipose or plasma concentrations in female 
      Sprague-Dawley rats 3 days after a single oral dose, relative to 
      2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Hepatic ethoxyresorufin-O-deethylase 
      activity and gene expression of Cyp1a1, 1a2, 1b1 and aryl hydrocarbon receptor 
      repressor in liver and peripheral blood lymphocytes were used as endpoints. 
      Results show that plasma-based systemic REPs were generally within a half log 
      range around the intake REPs for all congeners tested, except for 4-PeCDF. 
      Together with our previously reported systemic REPs from a mouse study, these 
      data do not warrant the use of systemic REPs as systemic TEFs for human risk 
      assessment. However, further investigation for plasma-based systemic REPs for 
      4-PeCDF is desirable.
FAU - van Ede, Karin I
AU  - van Ede KI
AD  - Institute for Risk Assessment Sciences, Utrecht University, P.O. Box 80177, 3508 
      TD, Utrecht, The Netherlands, k.i.vanede@uu.nl.
FAU - Andersson, Patrik L
AU  - Andersson PL
FAU - Gaisch, Konrad P J
AU  - Gaisch KP
FAU - van den Berg, Martin
AU  - van den Berg M
FAU - van Duursen, Majorie B M
AU  - van Duursen MB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131221
PL  - Germany
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
RN  - 0 (Benzofurans)
RN  - 0 (Dioxins)
RN  - 0 (Polychlorinated Dibenzodioxins)
RN  - 2B2AQE8U50 (2,3',4,4',5-pentachlorobiphenyl)
RN  - 2NE6H0QPCH (1,2,3,7,8-pentachlorodibenzo-p-dioxin)
RN  - 38380-08-4 (2,3,3',4,4',5-hexachlorobiphenyl)
RN  - DFC2HB4I0K (Polychlorinated Biphenyls)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
RN  - TSH69IA9XF (3,4,5,3',4'-pentachlorobiphenyl)
RN  - U4C2RV3124 (2,3,4,7,8-pentachlorodibenzofuran)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Benzofurans/administration & dosage/pharmacokinetics/toxicity
MH  - Body Weight/drug effects
MH  - Cytochrome P-450 CYP1A1/genetics/metabolism
MH  - Dioxins/*administration & dosage/*pharmacokinetics/toxicity
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Lymphocytes/drug effects
MH  - Polychlorinated Biphenyls/administration & dosage/pharmacokinetics/toxicity
MH  - Polychlorinated Dibenzodioxins/administration & dosage/analogs & 
      derivatives/pharmacokinetics/toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tissue Distribution
EDAT- 2013/12/24 06:00
MHDA- 2015/05/13 06:00
CRDT- 2013/12/24 06:00
PHST- 2013/10/18 00:00 [received]
PHST- 2013/12/12 00:00 [accepted]
PHST- 2013/12/24 06:00 [entrez]
PHST- 2013/12/24 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.1007/s00204-013-1186-2 [doi]
PST - ppublish
SO  - Arch Toxicol. 2014 Mar;88(3):637-46. doi: 10.1007/s00204-013-1186-2. Epub 2013 
      Dec 21.